HAYWARD, Calif.–(BUSINESS WIRE)–Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing a variety of molecular and combination therapies for patients with cancer, today announced that the Compensation Committee of the Board of Directors of the Company granted four new employees options to purchase a total of 66,900 shares of the Company’s common stock at an exercise price per share of $15.96, which was the closing price on December 23, 2024, and restricted stock units to acquire a total of 33,450 shares of the Company’s common stock. The equity awards were granted pursuant to the Company’s 2020 Inducement Plan, which was approved by the Company’s Board of Directors in January 2020 pursuant to the inducement exception under NYSE Listed Company Manual Rule 303A.08.

About Arcus Biosciences (NYSE:)

Arcus Biosciences is a clinical-stage, global biopharmaceutical company developing a variety of molecular and combination medicines for people with cancer. In collaboration with industry collaborators, patients and physicians worldwide, Arcus accelerates the development of first or best-in-class drugs against well-characterized biological targets and pathways and studies novel, biology-driven combination with the potential to help. people with cancer live longer. Founded in 2015, the company has accelerated the development of several investigational drugs in clinical studies, including new combination approaches targeting TIGIT, PD-1, HIF-2a, CD73, dual A2a/ A2b receptor, CD39 and AXL. For more information about Arcus Biosciences’ clinical and preclinical programs, please visit www.arcusbio.com.

Encourage PR

Source: Arcus Biosciences

See the original version on businesswire.com: https://www.businesswire.com/news/home/20241224871937/en/

Investor Questions:
Pia Eaves
VP of Investor Relations & Strategy
(617) 459-2006
[email protected]

Media Inquiries:
Holli Kolkey
VP of Corporate Communications
(650) 922-1269
[email protected]

Source: Arcus Biosciences